BRIEF-Oramed Reaches 25% Randomization In World's First Phase 3 Oral Insulin Study Conducted Under FDA Approved Protocol

Reuters · 03/16/2021 12:58
BRIEF-Oramed Reaches 25% Randomization In World's First Phase 3 Oral Insulin Study Conducted Under FDA Approved Protocol

March 16 (Reuters) - Oramed Pharmaceuticals Inc ORMP.O:

  • ORAMED REACHES 25% RANDOMIZATION IN WORLD'S FIRST PHASE 3 ORAL INSULIN STUDY CONDUCTED UNDER FDA APPROVED PROTOCOL

  • ORAMED PHARMACEUTICALS INC - ORA-D-013-1 STUDY IS RECRUITING 675 PATIENTS THROUGH 75 CLINICAL SITES THROUGHOUT U.S.

  • ORAMED PHARMACEUTICALS - ENROLLED, RANDOMIZED 25% OF 675 PATIENTS PLANNED FOR ITS PHASE 3 ORA-D-013-1 STUDY OF ITS ORAL INSULIN CAPSULE ORMD-0801

Source text for Eikon: ID:nPnbFLssNa

Further company coverage: ORMP.O


((Reuters.Briefs@thomsonreuters.com;))